Ketone Strip Recall Raises Risk of Delayed DKA Detection
Nova Biomedical’s StatStrip ketone test strips are facing a recall after specified lots were linked to repeated quality-control failures. The immediate clinical consequence is not simply a product withdrawal. In hospitals, urgent care units, ambulance services, community settings, and paediatric pathways, blood ketone testing is a frontline tool for identifying and tracking diabetic ketoacidosis before acidosis deepens and a patient deteriorates.
The company has paused distribution of the affected lots and warned that additional lots may also need to come out of clinical use if they fail QC testing. Replacement stock is not expected in the UK for about four weeks, creating a real risk of reduced availability across point-of-care services. In practice, that means clinicians may have less access to a test that often determines whether a patient can be observed, escalated, transferred, or treated for DKA without delay.
Why Blood Ketone Testing Matters at the Bedside
Blood ketone measurement is central to the assessment of patients with suspected or established DKA. Ketosis reflects the metabolic shift that occurs when insulin deficiency drives lipolysis and ketone production, while blood glucose alone may not capture the full severity of illness. When ketones rise above 3 mmol/L, NHS guidance treats that finding as a red flag for DKA requiring emergency assessment.
In emergency medicine and paediatrics, speed is not cosmetic. A child with vomiting, dehydration, abdominal pain, deep or rapid breathing, or reduced alertness may be moving quickly toward a life-threatening metabolic emergency. An adult with type 1 diabetes and worsening hyperglycaemia can be in the same danger zone, especially when serial ketone readings are needed to judge whether treatment is working. If the ketone result is delayed, clinicians lose time on the one decision that matters most: whether the patient is improving or sliding into more severe ketoacidosis.
The risk is greatest when no validated alternative method is immediately available. That is true in some pre-hospital services, urgent community response teams, hospital-at-home models, and smaller sites where laboratory testing is not on hand at the moment of need.
Supply Disruption Forces Triage of a Common Test
The recall creates a second problem beyond device quality: supply. Even lots not currently recalled may disappear from use if they fail QC testing, shrinking inventory in a progressive and unpredictable way. Local services are being told not to assume that existing stock will last for the period it appears to cover. A box on the shelf is not the same as confirmed usable capacity.
Healthcare organisations now need to map their remaining testing capability with precision. That means identifying which lots are in circulation, where the devices are located, how much usable stock remains, and when out-of-stock dates may arrive. It also means validating alternative ketone testing methods before the shortage becomes clinically disruptive. If another point-of-care device or a laboratory pathway can take over, it should already be tested, approved, and ready to use rather than improvised during a metabolic emergency.
One sentence captures the bedside consequence. If blood ketone testing is unavailable, DKA can be missed, treatment can be slowed, and deterioration can occur before escalation catches up.
Patients Most Vulnerable to Testing Gaps
The MHRA guidance places priority on the patients least able to absorb delay: those with suspected or established DKA, paediatric patients, acutely unwell people with type 1 diabetes, and anyone needing serial ketone checks during active treatment. Those groups depend on repeat measurements to confirm response to fluids, insulin, and electrolyte correction. Without that feedback loop, clinicians may struggle to know whether the metabolic trajectory is improving or whether a higher level of care is needed.
The risk extends beyond the hospital ward. Community services and ambulance clinicians may be the first to encounter a patient whose symptoms already suggest DKA. If ketone testing cannot be done immediately, transfer to an appropriate setting becomes more likely. In children and young people, the stakes are even higher: NICE recommends near-patient ketone testing when DKA is suspected, and where that is not available, immediate transfer to a hospital with acute paediatric facilities is advised.
Patients receiving advice from clinicians are being told to continue their prescribed sick-day or insulin plan unless directed otherwise, to keep checking blood glucose frequently if they have a meter or continuous glucose monitor, and to seek urgent care for vomiting, abdominal pain, fruity or pear-smelling breath, deep or rapid breathing, marked drowsiness, confusion, severe thirst, dehydration, or progressive illness. Those symptoms fit the clinical pattern of evolving DKA, and they should not be waited out at home.
Contingency Planning Becomes a Safety Issue
The advisory places governance teams, procurement leads, point-of-care testing leads, and clinical teams under the same operational requirement: maintain a documented contingency plan until confirmed, validated, quality-assured ketone-testing capacity can meet foreseeable demand. Local mitigation cannot push suspected DKA into a setting that lacks a reliable way to assess ketosis. That is particularly important in sites where a transfer decision is being made on the strength of a single bedside result.
Distributors have also been told to follow Nova Biomedical’s recall and stop-ship instructions and not to supply identified lots. Healthcare professionals are being directed to report incidents through the Yellow Card system in England and Wales, through IRIC and local systems in Scotland, and through Yellow Card reporting pathways in Northern Ireland.
The clinical gap is immediate and concrete: DKA is a potentially fatal emergency, and the loss of timely ketone testing can delay recognition, slow treatment decisions, and impair monitoring of response. The current alert is therefore not just a supply notice. It is a reminder that a reliable point-of-care assay can function as an early warning system, and when that system is unstable, services need another route in place before the first patient arrives.